---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006951"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:26:18.154726+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arbutus and Barinthus report preliminary Phase 2a data: imdusiran + VTP-300 sustains low HBsAg levels in cHBV

## Summary
- Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.
- Mean HBsAg reduction of -1.86 log10 after 24 weeks of imdusiran; all VTP-300 patients maintained <100 IU/mL through week 48.
- 60% of VTP-300 patients had HBsAg <10 IU/mL through week 48; all qualified to stop NA therapy.
- HBV-specific T cell IFN-γ production enhanced vs placebo; no serious AEs, Grade 3/4 AEs, or discontinuations.
- Updated corporate presentation posted on company website with additional pipeline details.

## SEC filing metadata
- accession: 0001171843-23-006951
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/0001171843-23-006951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/f8k_110923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006951
- JSON: https://secwatch.observer/filing/0001171843-23-006951.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.